NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent ...

Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is ...

A single 600 mg BRIUMVI infusion on Day 1 was well tolerated in individuals with RMS regardless of prior treatment or B-cell depletion status Rapid 30-minute BRIUMVI infusions were well tolerated ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Greetings, and welcome to TG Therapeutics First Quarter Conference ...

The potentially first-in-class drug, which targets CD20, is able to achieve "deep B-cell depletion" by stimulating cells of the immune system to engulf and destroy B-cells in the presence of a ...

Their stories echo findings from a recent paper in Frontiers in Immunology which highlighted seven case reports of people with MS who switched to BRIUMVI from a prior anti-CD20 due to issues like ...

TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.